Clinical Core

临床核心

基本信息

  • 批准号:
    8329981
  • 负责人:
  • 金额:
    $ 34.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-01 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY (See instructions): The Clinical Core of the FHI/RTI/UNC CFAR is led by Dr. Joseph Eron, Director, Dr. Prema Menezes, co-Director, and Dr. Sonia Napravnik, Core Epidemiologist, who also leads the UNC CFAR HIV Clinical Cohort (UCHCC). The goals of the Clinical Core are 1) to enhance the clinical, translational and epidemiological research capacity of a diverse array CFAR investigators by providing essential services such as subject recruitment, sample access and regulatory assistance, study design and management, study coordinator services and unique resources such as access to a detailed clinical cohort with links to larger cohorts and specimen and tissue repositories coupled with state-of-the-art epidemiological expertise and 2) to provide leadership and foster collaboration in high priority research areas and provide mentorship to students and faculty and educational opportunities to the wider community. The Core includes a dedicated staff of over 15 individuals with the needed skills to accomplish these goals. The Core is housed centrally on the UNC Health Affairs campus and is easily accessible to investigators either because of close proximity or because the leadership and several of our services are readily available electronically facilitating interactions with FHl, RTI and international investigators. The Core supports research from molecular to geographic (even combining the extremes) using methods ranging from patient oriented qualitative work to complex epidemiological modeling. Over the past four years the Core served over 100 investigators on over 150 projects supported by the NIH, the Agency for Health Care Research and Quality (AHRQ) and CDC among others. The Core supports multiple CFARiCFAR research projects and NIH-sponsored HIV networks while having a strong mentoring presence. The Core also provides data, leadership and investigator access to two large HIV-focused collaborative cohorts. The Clinical Core is essential for the continued success of the UNC/FHI/RTI CFAR as the services and research opportunities provided by the Core and the UCHCC have proved invaluable to investigators and are not duplicated by other Cores or facilities on the UNC, FHl or RTI campuses.
项目总结(见说明): FHI/RTI/UNC CFAR的临床核心由主任Joseph Eron博士、联席主任Prema Meneze博士和核心流行病学家Sonia Napravnik博士领导,她也是UNC CFAR HIV临床队列(UCHCC)的负责人。临床核心的目标是1)通过提供基本服务,如受试者招募、样本获取和监管援助、研究设计和管理、研究 协调服务和独特的资源,例如访问详细的临床队列,链接到更大的队列和标本和组织库,以及最先进的流行病学专业知识;2)在高度优先的研究领域提供领导和促进合作,并为学生和教职员工提供指导,为更广泛的社区提供教育机会。核心包括一个专用的 员工超过15人,具备实现这些目标所需的技能。核心中心位于北卡罗来纳大学卫生事务园区的中央,调查人员很容易接近,因为距离很近,或者因为领导层和我们的几项服务随时可以通过电子方式提供,从而促进了与FHL、RTI和国际调查人员的互动。 核心支持从分子到地理(甚至结合极端)的研究,使用的方法范围从以患者为中心的定性工作到复杂的流行病学建模。在过去的四年里,CORE为100多名研究人员提供了超过150个由美国国立卫生研究院(NIH)支持的项目的服务 关怀、研究和质量(AHRQ)和疾病预防控制中心等。该核心支持多个CFARiCFAR研究项目和NIH赞助的艾滋病毒网络,同时拥有强大的指导存在。该核心还提供数据、领导力和调查员访问两个以艾滋病毒为重点的大型合作队列。 临床核心对于北卡罗来纳大学/FHI/RTI CFAR的持续成功至关重要,因为CORE和UCCC提供的服务和研究机会对研究人员来说是宝贵的,不会被北卡罗来纳大学、FHL或RTI校园的其他核心或设施所复制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph J Eron其他文献

CD4 count at entry into HIV care and at antiretroviral therapy prescription in the US, 2005-2018.
2005-2018 年美国进入艾滋病毒护理和抗逆转录病毒治疗处方时的 CD4 计数。
  • DOI:
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    11.8
  • 作者:
    Jennifer S. Lee;E. Humes;B. Hogan;K. Buchacz;Joseph J Eron;M. Gill;Timothy R. Sterling;Peter F. Rebeiro;V. Lima;Á. Mayor;M. Silverberg;M. Horberg;Richard D. Moore;K. Althoff;Constance A. Benson;Ronald J. Bosch;Gregory D Kirk Emory;Kenneth H. Mayer;C. Grasso;Robert S. Hogg;P. Richard Harrigan;J. Montaner;B. Yip;Julia Zhu;K. Salters;Karyn Gabler;K. Buchacz;Jun Li;K. Gebo;Richard D Moore Johns;Richard D. Moore;John T. Carey;B. Rodriguez;M. Horberg;M. Silverberg;Jennifer E. Thorne;Todd Brown;Phyllis C. Tien;Gypsyamber D'Souza;F. Crouzat;Mona Loutfy;Graham Smith;Meenakshi Gupta;M. Klein;Charles S Rabkin;A. Kroch;Ann N. Burchell;Adrian Betts;Joanne D. Lindsay;A. Nijhawan;R. Hunter;Á. Mayor;M. John Gill;Jeffrey N. Martin;J. T. Brooks;M. Saag;M. Mugavero;James Willig;Laura Bamford;Maile Karris;Joseph J Eron;S. Napravnik;M. Kitahata;Heidi M Crane;Timothy R. Sterling;David Haas;Peter F. Rebeiro;M. Turner;Lesley Park;Amy C. Justice;K. Althoff;S. Gange;Jennifer S. Lee;R. Mckaig;Aimee M. Freeman;Stephen E. Van Rompaey;Liz Morton;J. McReynolds;William Lober;B. Hogan;Bin You;E. Humes;Lucas Gerace;Cameron Stewart;Sally B Coburn
  • 通讯作者:
    Sally B Coburn
Early antiviral CD4 and CD8 T cell responses are associated with upper respiratory tract clearance of SARS-CoV-2
早期抗病毒 CD4 和 CD8 T 细胞反应与 SARS-CoV-2 的上呼吸道清除相关
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    S. Ramirez;Paul G. Lopez;F. Faraji;U. Parikh;Amy L Heaps;J. Ritz;C. Moser;Joseph J Eron;David A Wohl;Judith S Currier;Eric S. Daar;A. Greninger;Paul Klekotka;A. Grifoni;D. Weiskopf;Alessandro Sette;Bjoern Peters;M. Hughes;K. Chew;Davey M. Smith;S. Crotty
  • 通讯作者:
    S. Crotty
Estimating multiple time‐fixed treatment effects using a semi‐Bayes semiparametric marginal structural Cox proportional hazards regression model
使用半贝叶斯半参数边际结构 Cox 比例风险回归模型估计多个固定时间的治疗效果
  • DOI:
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Stephen R. Cole;Jessie K. Edwards;D. Westreich;C. Lesko;B. Lau;M. Mugavero;W. C. Mathews;Joseph J Eron;S. Greenland
  • 通讯作者:
    S. Greenland
Association of immunosuppression and HIV viremia with anal cancer risk in persons living with HIV in the United States and Canada.
美国和加拿大艾滋病毒感染者的免疫抑制和艾滋病毒病毒血症与肛门癌风险的关联。
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    11.8
  • 作者:
    R. Hernández;L. Qin;Haiqun Lin;W. Leyden;Romain S. Neugebauer;K. Althoff;N. Hessol;Chad J. Achenbach;J. T. Brooks;M. Gill;S. Grover;M. Horberg;Jun Li;W. C. Mathews;Á. Mayor;P. Patel;Charles S Rabkin;A. Rachlis;Amy C. Justice;Richard D. Moore;Eric A. Engels;M. Silverberg;R. Dubrow;Constance A. Benson;Ronald J. Bosch;Gregory D Kirk;Kenneth H. Mayer;C. Grasso;Robert S. Hogg;P. Richard Harrigan;J. Montaner;B. Yip;Julia Zhu;K. Salters;Karyn Gabler;K. Buchacz;Jun Li;K. Gebo;Richard D. Moore;B. Rodriguez;M. Horberg;M. Silverberg;Jennifer E. Thorne;Charles S Rabkin;Joseph B. Margolick;Lisa P. Jacobson;Gypsyamber D'Souza;M. Klein;A. Kroch;Ann N. Burchell;Adrian Betts;Joanne D. Lindsay;R. Hunter;Á. Mayor;M. John Gill;S. Deeks;Jeffrey N. Martin;J. T. Brooks;M. Saag;M. Mugavero;James Willig;W. C. Mathews;Joseph J Eron;S. Napravnik;M. Kitahata;Heidi M Crane;D. Drozd;Timothy R. Sterling;David Haas;Peter F. Rebeiro;M. Turner;Amy C. Justice;R. Dubrow;David A. Fiellin;S. Gange;K. Anastos;K. Althoff;R. Mckaig;Aimee M. Freeman;Stephen E. Van Rompaey;Liz Morton;J. McReynolds;William Lober;Jennifer S. Lee;Bin You;B. Hogan;Jinbing Zhang;Jerry Jing;E. Humes;Sally B Coburn
  • 通讯作者:
    Sally B Coburn
HIV Viremia and Incidence of Non-Hodgkin Lymphoma in Patients HIV Viremia and Incidence of Non-Hodgkin Lymphoma in Patients Successfully Treated With Antiretroviral Therapy Successfully Treated With Antiretroviral Therapy
成功接受抗逆转录病毒治疗的患者中的 HIV 病毒血症和非霍奇金淋巴瘤的发病率 成功接受抗逆转录病毒治疗的患者中的 HIV 病毒血症和非霍奇金淋巴瘤的发病率
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Chad J Achenbach;Ashley L. Buchanan;Stephen R. Cole;Lifang Hou;M. Mugavero;Heidi M Crane;Richard D. Moore;Richard H. Haubrich;Satish Gopal;Joseph J Eron;Peter W Hunt;B. Rodriguez;Kenneth H. Mayer;M. Saag;M. Kitahata
  • 通讯作者:
    M. Kitahata

Joseph J Eron的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph J Eron', 18)}}的其他基金

HIV/AIDS Clinical Trials Unit (CTU) COVID-19 Admin Supplement
HIV/AIDS 临床试验单位 (CTU) COVID-19 管理补充资料
  • 批准号:
    10166401
  • 财政年份:
    2020
  • 资助金额:
    $ 34.51万
  • 项目类别:
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit
北卡罗来纳大学全球艾滋病毒预防和治疗临床试验单位
  • 批准号:
    10600176
  • 财政年份:
    2020
  • 资助金额:
    $ 34.51万
  • 项目类别:
Clinical Core
临床核心
  • 批准号:
    8531833
  • 财政年份:
    2013
  • 资助金额:
    $ 34.51万
  • 项目类别:
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)
北卡罗来纳大学艾滋病临床试验中心 (UNC ACTU)
  • 批准号:
    8076503
  • 财政年份:
    2010
  • 资助金额:
    $ 34.51万
  • 项目类别:
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)
北卡罗来纳大学艾滋病临床试验中心 (UNC ACTU)
  • 批准号:
    8033343
  • 财政年份:
    2010
  • 资助金额:
    $ 34.51万
  • 项目类别:
University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)
北卡罗来纳大学艾滋病临床试验中心 (UNC ACTU)
  • 批准号:
    7900104
  • 财政年份:
    2009
  • 资助金额:
    $ 34.51万
  • 项目类别:
MEASURE THE CLEARANCE OR REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+CELLS
测量静息记忆 CD4 细胞中的清除或复制能力 HIV-1
  • 批准号:
    7716768
  • 财政年份:
    2008
  • 资助金额:
    $ 34.51万
  • 项目类别:
CHAVI 001: ACUTE HIV-1 INFECTION PROSPECTIVE COHORT STUDY
CHAVI 001:急性 HIV-1 感染前瞻性队列研究
  • 批准号:
    7716860
  • 财政年份:
    2008
  • 资助金额:
    $ 34.51万
  • 项目类别:
PLAN FOR OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS
获得使用储存的人类生物材料的知情同意书的计划
  • 批准号:
    7716759
  • 财政年份:
    2008
  • 资助金额:
    $ 34.51万
  • 项目类别:
CLINICAL CORE
临床核心
  • 批准号:
    7644964
  • 财政年份:
    2008
  • 资助金额:
    $ 34.51万
  • 项目类别:

相似海外基金

AIDS Clinical Trial Group Laboratory Center
艾滋病临床试验组实验室中心
  • 批准号:
    10306319
  • 财政年份:
    2014
  • 资助金额:
    $ 34.51万
  • 项目类别:
AIDS Clinical Trial Group Laboratory Center
艾滋病临床试验组实验室中心
  • 批准号:
    9984198
  • 财政年份:
    2014
  • 资助金额:
    $ 34.51万
  • 项目类别:
AIDS Clinical Trial Group Laboratory Center
艾滋病临床试验组实验室中心
  • 批准号:
    10527322
  • 财政年份:
    2014
  • 资助金额:
    $ 34.51万
  • 项目类别:
AIDS Clinical Trial Group Laboratory Center
艾滋病临床试验组实验室中心
  • 批准号:
    10747032
  • 财政年份:
    2014
  • 资助金额:
    $ 34.51万
  • 项目类别:
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL
成人艾滋病临床试验组纵向连锁随机试验方案
  • 批准号:
    7718385
  • 财政年份:
    2008
  • 资助金额:
    $ 34.51万
  • 项目类别:
PEDIATRIC LATE OUTCOMES (AIDS CLINICAL TRIAL GROUP # 219)
儿科晚期结果(艾滋病临床试验组
  • 批准号:
    7603425
  • 财政年份:
    2007
  • 资助金额:
    $ 34.51万
  • 项目类别:
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL
成人艾滋病临床试验组纵向连锁随机试验方案
  • 批准号:
    7605681
  • 财政年份:
    2007
  • 资助金额:
    $ 34.51万
  • 项目类别:
PACTG(PEDIATRIC AIDS CLINICAL TRIAL GROUP) 1058 : PHARMACOKINETIC STUDIES
PACTG(儿科艾滋病临床试验组)1058:药代动力学研究
  • 批准号:
    7603580
  • 财政年份:
    2007
  • 资助金额:
    $ 34.51万
  • 项目类别:
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL
成人艾滋病临床试验组纵向连锁随机试验方案
  • 批准号:
    7378240
  • 财政年份:
    2006
  • 资助金额:
    $ 34.51万
  • 项目类别:
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) -
成人艾滋病临床试验组纵向连锁随机试验 (ALLRT) -
  • 批准号:
    7606380
  • 财政年份:
    2006
  • 资助金额:
    $ 34.51万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了